Administering a combination of Abraxane ® and Intralipid ® results in less of toxicity of the chemotherapy drug in the kidney (bottom row) than administering Abraxane ® alone (top row). (sciencedaily.com)
[3,4] Despite these advances, the late toxicities of chemotherapy and increased risk of secondary malignancies with RT have threatened the survival rates and quality of life of Hodgkin lymphoma patients. (cancernetwork.com)
Because of the toxicity of chemotherapy, no patient wants to find out by trial and error how his or her particular tumor will respond to a given drug. (the-scientist.com)